Fundz

Human cell programming company bit.bio closes $25M Series D funding to enhance its cell models and increase technology access. The investment includes support from M&G Investments and Dr Jonathan Milner.

PRIVATENov 04, 2026

Amount Raised

$25 Million

Round Type

Series D

CambridgeshireInformation TechnologyFinancial ServicesSoftwareScience And EngineeringPayments

Investors

Dr. Jonathan MilnerM&G Investments

Description

bit.bio has secured $25 million in Series D funding aimed at expanding its portfolio of human cell models for pharmaceutical companies and research organizations. This round follows an earlier Series C funding and addresses the growing demand for reliable human cell-based alternatives in drug discovery. The company's opti-ox™ platform enables consistent and scalable production of defined human cell types. With over 50 human cell types in its ioCells portfolio, bit.bio is positioned to lead in providing models for various applications in drug discovery and disease research.

Quick answer

bit.bio raised $25 Million in a Series D round, dated November 4, 2026. Investors: Dr. Jonathan Milner and M&G Investments. bit.bio is based in Cambridgeshire, England, United Kingdom.

How much did bit.bio raise?
bit.bio raised $25 Million in a Series D round on November 4, 2026.
Who invested in bit.bio?
Dr. Jonathan Milner and M&G Investments are named as investors in this round.
What does bit.bio do?
bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures.
Where is bit.bio based and how big is it?
bit.bio is based in Cambridgeshire, England, United Kingdom. Fundz records about 162 employees.
Who are the decision-makers at bit.bio?
Fundz holds 1 contact at bit.bio. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Financial Services and Science And Engineering around the same time

Companies in the same sectors as bit.bio that raised within 45 days of this round, from Fundz verified event records.

  • Billd raised $100M (Debt Financing) on November 5, 2026.
  • CellPoint Digital raised $34M on September 22, 2026.
  • Nova raised $24M (Series A) on November 12, 2026.
  • Palomma raised $10M (Series A) on November 12, 2026.
  • Numina raised $1.2M (Pre-Seed) on November 10, 2026.
  • Yoco raised $100M (Debt Financing) on November 10, 2026.

Who to call at bit.bio, and when

A new round usually means bit.bio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day bit.bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at bit.bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at bit.bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

bit.bio

Location

Cambridgeshire, England, United Kingdom

About

bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines. Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable research and drug discovery teams to accelerate their experimental timelines and reduce experimental variability, providing an important alternative to traditional workflows. We are also leveraging our platform to build a pipeline of txCells for cell therapies. To achieve our goals, we have assembled a team of pioneers in stem cell biology, cell programming, mathematical modelling and cell therapy. We are empirical, highly ambitious and driven by a shared vision. Collaboration is at the heart of bit.bio. Join us on our journey.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment bit.bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for bit.bio's next move

See what Strategic adds

bit.bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.